Phuturdex › Diseases › Bone neoplasm
Drugs in development · updated 30 October 2026
Bone neoplasm: drugs in development
As of 30 October 2026 there are 16 active clinical trials (recruiting or ongoing, phases I–III) on 25 drugs for bone neoplasm. 5 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| ZanzalintinibXL092 | II | 2 | NCT06571734 |
| Elraglusib Oral Tablets9-ING-41 | II | 1 | NCT03678883 |
| OST31-164 | II | 1 | NCT04974008 |
| 153Sm-DOTMP | I | 1 | NCT07197645 |
| Poly ICLCHiltonol | I | 1 | NCT04616248 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| CyclophosphamideCyclophosphamid, Cytoxan | II | 2 | NCT03449108 |
| DoxorubicinAdriamycin, Doxorubincin | II | 2 | NCT03678883 |
| GemcitabineGemcitabin, Gemzar | II | 2 | NCT03678883 |
| IrinotecanOnivyde, CPT-11 | I–II | 2 | NCT07853105 |
| AldesleukinProleukin | II | 1 | NCT03449108 |
| AlectinibAlecensa® | I–II | 1 | NCT07560410 |
| CarboplatinCarboplatine, Paraplatin | II | 1 | NCT03678883 |
| CisplatinCis Platinum, Cisplatine | I–II | 1 | NCT03965234 |
| EverolimusRAD001, Everoliumus | II | 1 | NCT07619950 |
| FludarabineFludara, FLUDARABIN | II | 1 | NCT03449108 |
| IpilimumabYERVOY, ipililumab IV | II | 1 | NCT03449108 |
| LenvatinibLenvatinib Mesilate Capsules, Levatinib | II | 1 | NCT07619950 |
| LomustineCCNU, Gleostine® | II | 1 | NCT03678883 |
| NivolumabOpdivo, ONO-4538 | II | 1 | NCT03449108 |
| PaclitaxelTaxol, Paxlitaxel | II | 1 | NCT03678883 |
Sorted by most advanced phase and number of active trials. Showing 15 of 20 drugs.
All 25 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Head and neck squamous cell carcinoma 321 drugs
- Mouth Neoplasms 49 drugs
- Tongue neoplasm 8 drugs
- Lip neoplasm 6 drugs
- Head and neck neoplasms 184 drugs
- Laryngeal neoplasm 35 drugs
- Hypopharyngeal Neoplasms 33 drugs
- Oropharyngeal Neoplasms 46 drugs
- Squamous cell carcinoma 72 drugs
Broader categories
- Musculoskeletal disorder 22 drugs
- Bone disease 9 drugs
- Neoplasm 671 drugs
- Sarcoma 204 drugs
- Skin disease 34 drugs
- Skin and connective tissue diseases 3 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D001859 “Bone Neoplasms”.